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Diagnostic tools for neurodegenerative diseases such as Alzheimer’s disease (AD)
currently involve subjective neuropsychological testing and specialized brain imaging
techniques. While definitive diagnosis requires a pathological brain evaluation at autopsy,
neurodegenerative changes are believed to begin years before the clinical presentation of
cognitive decline. Therefore, there is an essential need for reliable biomarkers to aid in
the early detection of disease in order to implement preventative strategies. microRNAs
(miRNA) are small non-coding RNA species that are involved in post-transcriptional gene
regulation. Expression levels of miRNAs have potential as diagnostic biomarkers as they
are known to circulate and tissue specific profiles can be identified in a number of
bodily fluids such as plasma, CSF and urine. Recent developments in deep sequencing
technology present a viable approach to develop biomarker discovery pipelines in order
to profile miRNA signatures in bodily fluids specific to neurodegenerative diseases. Here
we review the potential use of miRNA deep sequencing in biomarker identification from
biological fluids and its translation into clinical practice.
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INTRODUCTION
The pathophysiological process of neurodegenerative disorders
such as Alzheimer’s disease (AD) begins well before the diag-
nosis of clinical dementia. AD is characterized pathologically by
the presence of insoluble plaques and tangles composed of beta-
amyloid (Aβ) formed by sequential amyloid precursor protein
(APP) proteolysis and hyperphosphorlyated Tau (pTau) proteins
(Hardy and Allsop, 1991; Walsh and Selkoe, 2004; Cole and
Vassar, 2008). The accumulation of Aβ has been the major focus
of AD research and has been shown to interfere with long term
potentiation which is required for neuronal signaling, and is
implicated in pro-apoptotic signaling leading to neuronal loss
(Chapman et al., 1999; Roth, 2001). The majority of AD patients
are asymptomatic during the pre-clinical stages of the patholog-
ical process which is believed to be a period of approximately 17
years (Villemagne et al., 2013). Therefore, early diagnosis of AD
is required before or during the pre-clinical phase in order that
therapeutic intervention, or the use of disease modifying drugs,
can be administered.
The main biomarker targets currently employed for AD diag-
nosis are measurements of Aβ and pTau (Hansson et al., 2010;
Prvulovic and Hampel, 2011; Watt et al., 2011; Rosenmann,
2012). MicroRNA (miRNA) are a class of non-coding RNA
of approximately 22 nucleotides in length, and are known to
regulate post-translational transcription. Expression profiling of
miRNA levels represents a new class of potential biomarkers that
are currently being investigated for the diagnosis of a number
of diseases (Skog et al., 2008; Taylor and Gercel-Taylor, 2008;
Baraniskin et al., 2012b; Geekiyanage et al., 2012; Jones et al.,
2012). miRNAs are derived from RNA hairpins comprising of
precursor miRNA and processed by endoribonucleases (Dicer
and Drosha) to formmature miRNA fragment (Krol et al., 2010).
The mature miRNA is incorporated into the RNA-induced silenc-
ing complex (RISC) which binds to complementary sites in the
3′ untranslated region of their mRNA targets resulting in down-
regulation of gene expression (He and Hannon, 2004). They can
be secreted into biological fluids where they can be detected
and profiled using methods including quantitative real-time PCR
(qRT-PCR), microarrays, and more recently by deep sequencing
technologies.
Here, we review the current literature to highlight the diagnos-
tic potential to screen for neurodegeneration using gene expres-
sion profiling in biological fluids. In particular, we have focused
on the potential of profiling miRNA expression associated with
AD and evaluate the current deep sequencing platforms suit-
able for biomarker discovery including the implementation into
clinical diagnostic laboratories.
BRAIN-ASSOCIATED MICRORNAS AND THEIR DETECTION
IN BIOLOGICAL FLUIDS
It has been revealed that the highest expression of tissue spe-
cific miRNA is found in the brain (Babak et al., 2004; Sempere
et al., 2004; Schonrock et al., 2010). The significance of miRNA
and their conclusive biological functions were gradually discov-
ered using knockout mouse models (Schaefer et al., 2007). For
example, Dicer knockout mice have been shown to deregulate
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miRNA processing, leading to defects in neuronal development
and underdevelopment of the brain, demonstrating a role for
miRNA in neurogenesis (Schaefer et al., 2007; Kawase-Koga et al.,
2009; Huang et al., 2010). The first reports translating early
miRNA studies to the brain observed a number of brain enriched
miRNA such as miR-9, miR-29a, miR-125, miR-128, miR-134,
and miR-137 (Table 1). With respect to AD, a number of dereg-
ulated miRNA have been identified to correlate with disease,
including miR-9, miR-20a, and miR-132 (Makeyev et al., 2007;
Cogswell et al., 2008; Hebert et al., 2009, 2012). While, synthetic
miRNA precursors, miR-20a, miR-17-5p, and miR-106b, when
co-transfected in HeLa cell lines, inhibited APP protein transla-
tion (Hebert et al., 2009). Highly abundant and brain enriched
miRNAs found to be deregulated in ADmodels (human andmice
models) are summarized in Table 1.
Extracellular miRNA originating from specific tissues such
as the brain and cancerous tissues can be released into biolog-
ical fluids for example, Cerebral spinal fluid (CSF) (Cogswell
et al., 2008; Baraniskin et al., 2012b), blood (Hunter et al., 2008;
Baraniskin et al., 2011), saliva (Patel et al., 2011; Ogawa et al.,
2013) and urine (Gilad et al., 2008; Qi et al., 2012). Despite the
presence of high RNase activity, circulating miRNAs are protected
from degradation by binding to RNA binding proteins such as
lipoproteins (Arroyo et al., 2011; Vickers and Remaley, 2012)
or contained in membrane derived microvesicles, in particular,
exosomes (Mitchell et al., 2008; Arroyo et al., 2011). Exosomes
are formed within multi-vesicular bodies (MVBs) in the endoso-
mal system, which co-ordinates the transport of cargo between
the plasma membrane, trans-Golgi network (TGN) and lysoso-
mal system [reviewed in (Bellingham et al., 2012b)]. Exosomes
can function as an intercellular delivery mechanism by send-
ing miRNA cargo to initiate cell-to-cell communication as they
shuttle between neighboring and distant cells (Valadi et al., 2007).
Profiles of deregulated miRNA isolated from peripheral blood
(Jin et al., 2008) and serum (Skog et al., 2008; Taylor and Gercel-
Taylor, 2008; Edbauer et al., 2010) have been demonstrated and
suggest they have diagnostic potential for human diseases such as
cancer. For example, the pathology of various cancers andmiRNA
originating from the site of metastasis correlate positively in both
plasma and serum (Skog et al., 2008; Tsujiura et al., 2010). The use
of miRNA expression levels as biomarkers can be applied to other
human diseases and has not been thoroughly investigated in neu-
rodegenerative diseases such as AD. There are some limitations to
this approach, in particular the transport of brain specific miRNA
through the blood brain barrier (BBB) into the circulation sys-
tem of which the current mechanism is unknown. The BBB serves
as a tight control point that has specialized molecular machinery
to regulate the transport of nutrients and macromolecules, while
ensuring viruses and bacteria do not cross the barrier (Begley and
Brightman, 2003). On the contrary, under normal conditions, Aβ
is cleared from the brain and transported across the BBB medi-
ated by low-density lipoprotein receptor-related protein (Tanzi
et al., 2004), suggesting the possibility of other neurodegenerative
disease markers crossing the BBB.
There are two possible mechanisms by which miRNAs are able
to transport through the BBB. Firstly, a number of neurologi-
cal diseases such as Multiple Sclerosis and meningitis are well
known conditions that weaken and eventually disrupt the BBB,
consequently permitting a non-specific release of cellular factors
and nucleic acids (Begley and Brightman, 2003). Moreover, thin-
ning and perforations of the vascular basement membrane have
been observed in post-mortem brains of late-stage AD patients
(Blennow et al., 1990; Berzin et al., 2000; Zipser et al., 2007).
Secondly, exosomes and microvesicles may play an important
role as carriers of miRNA across the endothelial cellular lay-
ers of the BBB in order to communicate between the brain and
distant organs via biological fluids (Haqqani et al., 2013). A
proposed mechanism involves the transcytosis of extracellular
vesicles, such as exosomes, across endothelial cells of the BBB
by receptor-mediated endocytosis and releasing exosomal con-
tents into circulation. As a result, the contents of the vesicles
can be used as biomarkers reflective of the brain (Haqqani et al.,
2013). miRNAs found highly abundant in the brain have been
detected in human biological fluids such as plasma, urine, and
CSF (summarized in Table 1).
DETECTION OF microRNA IN BLOOD
Blood is a highly reliable specimen used for diagnostic testing,
with the majority of blood tests being minimally invasive. The
cellular components of blood (red blood cells, white blood cells
and platelets) provide a rich source of RNA species suitable for
biomarker analysis. The most abundant source of miRNAs in
blood are found in white blood cells (WBCs). The analysis of
miRNA in cellular components of the blood may provide an
understanding into the indirect causes of neurodegeneration or
indeed reveal information on the pathogenesis of sporadic AD
(Schipper et al., 2007; Xu et al., 2007). However, as the brain
derived miRNA signal is essentially diluted in the circulating
blood, there lies a greater signal-to-noise ratio.
In order to detect disease-specific miRNA profiles, the anal-
ysis of plasma and serum (cell-free) samples is most commonly
performed (Chen et al., 2008; Pareek et al., 2011; Turchinovich
et al., 2011), whereby a smaller but specific pool of miRNAs can
be detected. The appeal in detecting circulating miRNA profiles
is the potential of capturing the intracellular cross-talk between
neighboring and distant cells in the body (Valadi et al., 2007;
Turchinovich et al., 2011; Jones et al., 2012). Only a hand-
ful of studies have profiled miRNA biomarkers in AD patients
using plasma and serum samples. The expression levels of brain-
enriched miRNAs (miR-137, miR-9, miR-29a, andmiR-29b) have
been found to be significantly down regulated in plasma collected
from probable AD patients (Geekiyanage et al., 2012). In another
study, miR-128 and miR-134 were found to be highly abundant
in the brain, and were also detected in cases of mild cognitive
impairment (MCI), which is an early form of AD (Sheinerman
et al., 2012). Furthermore, it is possible to isolate exosomes
from plasma and serum to profile exosomal-specific miRNA
by differential ultracentrifugation (Skog et al., 2008; Taylor and
Gercel-Taylor, 2008).
DETECTION OF microRNA IN CSF
Identifying circulating miRNA biomarkers in blood represents
a clinical advantage for early disease diagnosis however, dif-
ferential miRNA expression may not accurately reflect miRNA
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deregulation in neuronal tissues subject to neurodegenerative dis-
ease. CSF is a clear biological fluid produced in the choroid plexus
of the brain, and circulates though the inner ventricular system,
across the BBB and is absorbed into the bloodstream. CSF repre-
sents a more suitable and relevant source of material for diagnosis
of central nervous system (CNS) disorders. CSF is obtained by
lumbar puncture and has been shown to contain circulating miR-
NAs that have been utilized in several studies for miRNA profiling
of neurological and neurodegenerative disorders; including AD
(Cogswell et al., 2008; Alexandrov et al., 2012; Lehmann et al.,
2012), schizophrenia (Gallego et al., 2012), Multiple Sclerosis
(Haghikia et al., 2012), HIV-encephalitis (Pacifici et al., 2013),
traumatic brain injury (Balakathiresan et al., 2012; Patz et al.,
2013) and various cancers of the CNS (Baraniskin et al., 2012a,b;
Teplyuk et al., 2012).
Studies of CSF from AD patients have used either a combi-
nation of miRNA microarrays (Alexandrov et al., 2012; Lukiw
et al., 2012), multiplex miRNA qPCR assay (Cogswell et al., 2008)
or a target candidate miRNA approach (Lehmann et al., 2012)
to identify differentially expressed miRNA. In these studies, no
correlation was observed between independent research groups
or when validated in corresponding tissues samples extracted
from AD patients (Cogswell et al., 2008). Using microarrays and
qPCR validation, miR-9, miR-146a and miR-155 were found to
be significantly up-regulated in AD patient CSF compared to age-
matched controls (Alexandrov et al., 2012; Lukiw et al., 2012).
However, these miRNAs were not identified in an independent
study in which 60 miRNAs were found to be deregulated in CSF
and corresponding brain tissue from AD patients (Cogswell et al.,
2008). Likewise, candidate miRNA let-7b found increased in AD
CSF (Lehmann et al., 2012) was not significantly altered in previ-
ous studies (Cogswell et al., 2008; Alexandrov et al., 2012; Lukiw
et al., 2012). These observations highlight the need for a uniform
approach to miRNA profiling for disease diagnosis. Collection
of brain tissue, CSF, and peripheral blood samples in the same
subjects would be advantageous however, this approach is chal-
lenging due the difficulty in recruiting study participants willing
to undergo multiple invasive procedures.
DETECTION OF microRNA IN URINE
Clinically, urine is collected non-invasively for biomarker discov-
ery and diagnostic purposes. The procedure for urine collection
is relatively time- and cost-efficient compared with other clini-
cal samples such as blood and CSF. This has led to an increase in
miRNA biomarker studies examining urine samples to screen for
disease biomarkers (Weber et al., 2010; Bryant et al., 2012; Wang
et al., 2012a). Circulating extracellular miRNAs can be delivered
to renal epithelial cells and released into the urine bound to RNA-
binding proteins or packaged into microvesicles such as exosomes
(Weber et al., 2010). The urine sediment, including whole cells,
cell debris and polymerized protein, is able to be separated from
whole urine using low-speed centrifugation (Wang et al., 2010,
2012a). Many studies exploit the urine cellular sediment obtained
from low speed centrifugation to analyse miRNA implicated in
prostate and bladder cancers (Wang et al., 2010, 2012c). Bryant
et al. have reported several deregulated miRNAs associated with
prostate cancer which were validated in serum, plasma and urine
(Bryant et al., 2012). Analysis of urinarymiRNA from the cell sed-
iment may not be suitable for neurodegenerative diseases, as it is
rich with cells or cell debris of hematologic origin, renal epithe-
lial origin and urothelial origin in addition to microorganisms
such as bacteria and yeast (Koss and Sherman, 1984; Wang et al.,
2010). Fewer studies have analysed cell-free urine to isolate miR-
NAs, mainly because it may contain miRNAs from organs of the
body outside of the excretory system. Exosomes can be purified
from urine using a differential ultracentrifugation method which
is the most widely applied technique (Alvarez et al., 2012). Future
advances in methodologies to improve sensitivity and accuracy
in profiling urinary miRNA biomarkers, in particular from using
exosomes, would be of great value to investigate whether miRNA
can be detected in urine.
Many studies using human cell lines differentiated with all-
trans-retinoic acid, cultured primary neurons, astrocytes and
brain sections from mice and human models highlight the sig-
nificance of miRNA in neurodegeneration (Sempere et al., 2004;
Smirnova et al., 2005; Alvarez et al., 2012). Overall, the poten-
tial to detect miRNA in biological fluids, in particular those
highly expressed in the brain, is well supported by research pub-
lished in the literature (summarized in Table 1). The majority
of experimental methods have used Northern blotting, qPCR
and microarrays though these methodologies are not suitable for
biomarker discovery or mass screening programs. Researchers
are now developing high-throughput, cost effective strategies to
improve the sensitivity and specificity of for miRNA diagnostics
in biological fluids. One of these technologies is deep sequencing.
THE USE OF DEEP SEQUENCING TECHNOLOGY TO SCREEN
FOR MICRORNA BIOMARKERS
Implementing deep sequencing technology represents a power-
ful and innovative approach to discover differentially expressed
miRNAs in neurodegenerative diseases (Brase et al., 2010; Debey-
Pascher et al., 2012). The advantage of using deep sequencing,
unlike traditional Sanger sequencing, lies upon the capability
to simultaneously process millions of independent sequencing
events. This offers billions of nucleotide information within a
single experiment (Shendure et al., 2004; Church, 2006). Deep
sequencing experiments enable comprehensive analyses of large
amounts of sequence data, resulting in dramatically accelerated
research compared to traditional labor-intensive efforts and is a
powerful approach to determine accurate encoded-information
from nucleotide fragments (Hall, 2007; Shendure and Ji, 2008;
Tucker et al., 2009).
LARGE-SCALE DEEP SEQUENCING PLATFORMS
Detecting low abundance or differentially expressed circulat-
ing miRNA signatures in biological fluids requires a large-
scale and high-throughput platform. The large-scale sequencing
instruments presently available are the 454 Genome Sequencer
(GS) FLX+ system from 454 Life Sciences, 5500 Sequencing
by Oligo Ligation Detection (SOLiD) system from Applied
Biosystems (Life Technologies), HiSeq 2000 system from Illumina
and the recently introduced Ion Proton from Ion Torrent
(Life Technologies). Each platform employs different sequenc-
ing chemistries for data generation (summarized in Table 2). All
Frontiers in Genetics | Non-Coding RNA August 2013 | Volume 4 | Article 150 | 4
Cheng et al. miRNA as biomarkers for Alzheimer’s disease
Table 2 | Specifications of current “Next-Generation” Deep Sequencing platforms† .
Sequencing
platform
Read length
(bases)#
Throughput /
time per run
Accuracy (%) Advantages Disadvantages Cost per run
Illumina
HiSeq™
2000
35–100 100–600Gb /
2–11 days
98.0 Ultra high throughput
High capacity of
multi-plexing
Short read assembly may miss
large structural variations
Signal interference among
neighbouring clusters
Homopolymer errors
$$$
Applied
Biosystems
5500
SOLiD™
35–75 120Gb / 7–14
days
99.9 Ultra high throughput
Two-base coding (higher
accuracy)
High capacity of
multi-plexing
Short read assembly may miss
large structural variations
Long run time
Signal interference among
neighbouring clusters
Signal degradation
$$$
Roche (454
Life
Sciences)
GS FLX
Titanium
700–1000 0.7Gb /
0.35–0.42 days
99.9 Long read assembly
allows detection of large
structural variations
Short run time
Lower throughput
Homopolymer errors
Signal interference among
neighbouring clusters
$$
Ion Torrent
Ion Proton™
PI
PII
100–400
100–400
10Gb / 4 h
30Gb / 4 h
98.5 Fast run time
Highly scalable (different
chips available)
Low cost
Newest to the market $/$$
Ion Torrent
Ion PGM™
314 chip
316 chip
318 chip
100–400
100–400
100–400
0.01Gb / 1 h
0.1Gb / 2 h
1Gb / 3 h
98.5 Highly scalable (different
chips available)
Low cost
Fast run time
Homopolymer errors $
Illumina
MiSeq™
35–150 1.5Gb / 27 h 99.2 Well-proven sequencing
technology
Fully automated
workflow
Low cost
Fast run time
Low abundance of amplified
template
$
Roche (454
Life
Sciences)
454 GS
Junior
250–400 0.035Gb / 8 h 99.0 Long read length
Relatively fast run time
Lower throughput
Homopolymer errors
$
# Average read length depends on specific sample and genomic characteristics.
† Specifications for all platforms are derived from company websites.
454 systems adopt a principle of pyrosequencing which, is based
on the detection of pyrophosphate molecules during nucleotide
incorporation and the intensity of signals produced by chemi-
luminescence (Ahmadian et al., 2006; Rothberg and Leamon,
2008). SOLiD utilizes ligation-based chemistry with dye-labeled
probes, involving rounds of oligonucleotide ligation extension
and two-base encoding detection (Pandey et al., 2008). Illumina
systems rely on a sequencing-by-synthesis (SBS) approach involv-
ing cycles of nucleotide incorporation and use of reversible dye
terminators (Fuller et al., 2009). Ion Proton also employs SBS
chemistry however, it measures signals through the production of
hydrogen ions resulting from the process of nucleotide replication
on a chip containing an array of semiconductor sensors (Rothberg
et al., 2011). Despite the various sequencing chemistries, all large-
scale deep sequencing platforms are capable of generating up to
3 billion sequencing reads, with an output of 0.7–600 gigabases
(Gb), quickly and efficiently (Table 2). To date, many unbiased
miRNA biomarkers have been discovered through large-scale
deep sequencing techniques (Maes et al., 2009; Cortez et al., 2011;
Etheridge et al., 2011; Bellingham et al., 2012a). However, deep
sequencing of small sample sizes via large-scale platforms will
be very expensive if the capacity of each run is not fully utilized
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(Wall et al., 2009). Furthermore, the advantages of these large-
scale platforms are immediately offset by the reagent costs, in
the thousands of dollars per sequencing run, and run times of
up to 14 days, which are usually constrained in small laborato-
ries and particularly in diagnostics (Morozova and Marra, 2008).
In order to facilitate access of deep sequencing for the majority
of laboratories, the recent launch of small-scale benchtop deep
sequencers has offered a cheaper alternative to sequence genomes
with greater speed, ∼2 h run time, and lower cost compared to
large-scale deep sequencer (Eyre et al., 2012).
BENCHTOP DEEP SEQUENCING PLATFORMS
The smaller benchtop deep sequencing instruments allow the
possibility of small-scale biomarker discovery. Commonly used
small-scale sequencing instruments are 454 GS Junior from
454 Life Sciences, MiSeq from Illumina, Ion Personal Genome
Machine (PGM) from Ion Torrent (summarized in Table 2).
The employment of benchtop sequencers offers an alternative
option for low number of samples in a cohort (Kumar and
Webster, 2011) and present additional advantages with their con-
venience of storage and simple procedures in sample preparation
(Hutchison, 2007; Eyre et al., 2012; Wilson, 2012). Loman et al.
and Quail et al. sequenced bacterial genomes, using laser-printer
sized benchtop platforms capable of generating usable sequences
with fast turnaround time in a straightforward workflow and
low running costs. In early 2010, the release of 454GS Junior
instrument substituted the larger 454GS FLX instrument for
small-scale sequencing. It employs similar template amplification
and pyrosequencing-based approaches as of the 454 higher-scale
sequencer (Margulies et al., 2005). Illumina and Ion Torrent also
provide for large and small-scale projects with the introduction
of Illumina MiSeq and Ion PGM, smaller versions of the Illumina
HiSeq and Ion Proton, respectively. These exploit the existing
platform-specific sequencing chemistry suitable for smaller scale
projects (Bentley et al., 2008). All benchtop sequencers are as
competitive as their respective large-scale platforms as they are
able to generate millions of reads in their output (Loman et al.,
2012a; Quail et al., 2012). Although both 454 JS Junior and
IlluminaMiSeq utilize years-proven sequencing strategies, the Ion
PGM is a useful addition to the current deep sequencing plat-
forms by adding scalability (i.e., different chips to allow different
scale of studies to be sequenced cost-efficiently) and lower instru-
ment cost (Defrancesco and Subbaraman, 2011; Scholz et al.,
2011; Kodama et al., 2012; Vogel et al., 2012). The output of
sequencing reactions ranges from 10-, 100-, to 1000-million reads
due to the availability of three different chips used for sequenc-
ing (e.g., 314-, 316-, and 318-chips). The signal detection of each
nucleotide in Ion Torrent system depends on a sensitive pH mea-
surement, thus eliminating the requirement for modified chemi-
luminesecent reporters and expensive detector devices (Pareek
et al., 2011). In essence, benchtop deep sequencing technolo-
gies provide an affordable way to produce accurate throughput
with sufficient sequencing coverage. Notably, Ion Proton can be
classified as benchtop sequencer as it is currently the only instru-
ment promised to provide shorter sequencing time than other
large-scale systems and hundred folds more data output than
other bench-top sequencers. Once these advantages are tested
in future studies, Ion Proton could have its own niche bridg-
ing between small-scale and large-scale for routine full genome
screening.
BIOMARKER DISCOVERY TO CLINICAL PRACTICE
Typically, the data generated from benchtop deep sequencing
instruments (e.g., high assembly coverage by 454GS Junior due
to long read length) are generally sufficient to obtain disease
specific profiles from individual samples (Loman et al., 2012b).
Ultimately, the choice of platform will depend on its performance
metrics (i.e., read length, accuracy and data output) to comple-
ment the type of study being undertaken. For clinical practice,
platforms such as the Ion PGM and MiSeq offer the best value
for money, more flexibility, accuracy, adequate throughput and
coverage depths for study of miRNA.
To incorporate miRNA deep sequencing for clinical practice,
a simple and standardized workflow for the routine biomarker
and diagnostic screening needs to be defined (Barzon et al.,
2011; Natrajan and Reis, 2011; Radford et al., 2012; Rizzo
and Buck, 2012). A typical workflow involved in performing
miRNA-sequencing from sample preparation to data analysis is
outlined in Figure 1. The sequencing workflow consists of the
following steps: (i) miRNA isolation; (ii) Library preparation
and enrichment of templates containing size selected libraries
of the appropriate fragment length; (iii) and Sequencing reac-
tion. Isolation of low abundance miRNA present in body fluids
(e.g., blood and urine) can be obtained by the use of RNA
isolation columns that specifically enrich for miRNA (Mitchell
et al., 2008; Arroyo et al., 2011). Preparation of isolated miRNA
for sequencing includes the assessment of quality (i.e., RNA
integrity number; RIN), profiling and quantification of small
RNA species, in particular miRNA (Ozsolak and Milos, 2010).
Preparation of sample library often requires barcoding, which
involves ligation of different adaptors of identifiable sequences
to either end of each sample. This method is to increase capac-
ity as it allows multiplexing of samples in the same sequencing
reaction (Chen et al., 2012). Template preparation for sequenc-
ing and the sequencing reaction is platform specific as seen
in Table 2.
Another approach to increase throughput is by capturing and
sequencing disease specific targets known as sequence enrich-
ment. In clinical practice, the factors to consider while sequencing
for an enriched population of targets may involve the size of
the region of interest, capture efficiency of interest region, aver-
age read depth coverage of the targeted region, distribution of
coverage and its sensitivity and specificity (Mamanova et al.,
2010). The quality control involved would require a set of posi-
tive and negative control references to establish a standard depth
and quality percentage of targeted regions for determining the
accuracy of enrichment (Harismendy et al., 2009; Teer et al.,
2010). Furthermore, reference controls eliminate any experimen-
tal problems which may arise from sequence variations that affect
hybridization to biotinylated probes during enrichment, causing
low capture efficiency (Schwartz et al., 2011). Hence, quality con-
trol measures should be routinely assessed before proceeding to
analyse samples for a diagnosis to eliminate false positives which
may be caused by poor miRNA quality or technical artefacts
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FIGURE 1 | A miRNA-sequencing workflow. The workflow consists
of sample preparation, sequencing, assessment and alignment,
expression profiling and final selection. Sequencing involves sample
preparation of isolated miRNAs to generate a library for the
sequencing reaction. Assessment and alignment requires
bioinformatics tools to generate usable mapped sequences. Final
selection of miRNAs related to the disease are filtered by
sophisticated statistical tools.
(Fehniger et al., 2010; Lee et al., 2010). Furthermore, instruments
that provide a fast turn-around time will be suitable in diag-
nostic laboratories in order to produce diagnostic reports in a
timely manner (Tucker et al., 2009). In clinical practice, a high
throughput strategy may involve using deep sequencing plat-
forms to screen for AD biomarkers by indexing a large number
of patient samples and pooling samples into one sequencing run.
Indexing patient samples and batch testing in a diagnostic labo-
ratory would be a cost-effective and practical approach to handle
large population screening.
All deep sequencing instruments produce a massive quan-
tity of raw data that requires extensive computational tools
to process the information (Zhang et al., 2011). Open-source
tools and in-house (Perl) scripts are available for handling large
quantities of sequencing data by providing an integrated and
streamlined analysis workflow (Nix et al., 2010). A fundamen-
tal workflow for post-analytic miRNA data analysis (Figure 1)
consists of four fundamental steps: (i) Sequence assessment; (ii)
Sequence alignment; (iii) Profiling of miRNA associated with
neurodegenerative disease; (iv) and Final selection. This work-
flow requires databases and tools such as FastQC (quality control
check), miRbase/miRandola (miRNA database), bowtie (short
read aligner) and EdgeR/DESeq (normalization) (Horner et al.,
2010; Kozomara and Griffiths-Jones, 2011; Russo et al., 2012).
In order to make data analysis more accessible to the diag-
nostic end-user, there are a number of commercially available
software packages that aim to make analysis uncomplicated by
providing user-friendly graphical interfaces (Richter and Sexton,
2009). This includes Partek Genomics Suite, CLC Genomics
Workbench, Ingenuity Systems and platform-specific software
(e.g., Ion Torrent Suite and Illumina GenomeStudio). These com-
mercial software tools have less flexibility and scalability in terms
of their parameters’ settings, but are suitable for small-scale
studies to establish miRNA profiles and perform differential
expression analysis in order to detect disease specific miRNA
(Meldrum et al., 2011).
CONCLUSIONS
Early diagnosis of AD is critical as it is hypothesized that the
pathology of the disease occurs up to 20 years before cogni-
tive decline. Many groups have searched for protein biomarkers
in blood, plasma, serum and CSF have not yielded a reliable,
sensitive, and specific candidate biomarker marker for AD diag-
nosis. Due to the sensitivity of deep sequencing, it is possible
to detect genetic modifications in disease, in particular dereg-
ulated miRNA. The possibilities of profiling miRNA in CSF,
urine, blood, plasma and serum have been explored with some
successes in cancer and may be applicable to AD and other
neurodegenerative disorders. In addition, the genetic informa-
tion contained in circulating exosomes may provide a highly
specific readout of disease and should be further investigated.
Deep sequencing of miRNA together with high-throughput val-
idation methods will complement diagnostic testing and rep-
resents a vital step toward developing a cost-effective, non-
invasive and low risk diagnostic test to detect the onset and
monitor various stages of AD. Furthermore, the development
of a diagnostic test comprising of a profile of RNA biomark-
ers associated with AD, and has potential for other neurode-
generative diseases such as Parkinson’s, Prion and Huntington’s
diseases.
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